MUMBAI-based pharmaceutical giant Cipla has opened its Australian headquarters in Melbourne. Cipla is the world’s largest manufacturer of antiretroviral drugs for patients with HIV/AIDS and has a turnover of US$1.4 billion per annum and more than 20,000 employees worldwide. One of the first investments by the company in a regional office outside India, the local office was officially opened by Dr Amanda Caples, Executive Director, Science & Technology Programs on behalf of the Victorian Govt. “Through our local staff Cipla will provide superior service to existing customers, build its customer base and provide expert advice to our R&D department on requirements of the Australian medicines market for future product opportunities,” said Oskar Hakansson, Cipla Head – Australia & New Zealand. Hakansson is pictured right with Dr Caples opening the new Melbourne headquarters.
PHARMACISTS have a valuable role to play in the detection and resolution of drug-related problems as part of a general practice team, according to a new study based on the outcomes of a six month trial in Western Sydney.
AS IF pharmaceutical brand originators didn’t have enough to worry about with generic copies of their drugs, now it appears that the brand originator can get into trouble when a generic causes harm that had not been identified and warned about by the original research company.